Liquidia Corporation (LQDA) Balance Sheet

The asset base expansion is driven by a surge in cash and receivables from the generic treprostinil distribution ramp, which also improved equity through retained earnings. However, the trajectory is heavily dependent on the sustainability of the generic revenue stream and the successful launch of YUTREPIA, as the recent positive net income is a recent development.

The sharp increase in debt in 2025 likely funded commercial preparation and litigation, but the subsequent reduction indicates either conversion to equity or repayment from operating cash flow. The current low leverage provides financial flexibility, but the company's history of volatile debt levels warrants monitoring, especially if litigation delays YUTREPIA and forces additional borrowing.

The growing cash position provides a runway for operations and legal expenses, while the increase in PPE suggests preparation for commercial-scale production of YUTREPIA. Goodwill remains minimal at $3.9M, reducing impairment risk, but the asset base is still heavily weighted toward current assets, reflecting the early-stage nature of the business.

The equity increase is primarily driven by new share issuances, as evidenced by the jump from $44.7M in 2025Q4 to $195.1M in 2026Q2, which likely funded debt repayment and operations. While retained earnings are still deeply negative, the recent positive net income suggests a potential inflection, but dilution risk remains if further capital is needed.

The current ratio has been volatile, dipping to 1.40 in 2025Q4 when debt was high, but has since recovered. The cash position of $284.2M, combined with positive operating cash flow in 2026Q2, suggests adequate liquidity to fund ongoing litigation and commercial launch activities. However, the company's negative operating margins historically indicate that cash burn could accelerate if revenue growth stalls.